HHS Price Forum: Surprisingly Good Context For Pharma Ideas For Regulatory Changes
This article was originally published in RPM Report
Executive Summary
The Obama Administration’s public forum to discuss responses to high drug prices sounded like a major threat to innovator companies. But it provided a setting to press for changes in marketing regulation sought by industry for years.
You may also be interested in...
CMS Medicare Center Director Seshamani Will Steer Coverage Decision On Aduhelm
Meena Seshamani served in the Obama Administration as head of the health reform office within the Health and Human Services Department.
Off-Label Communication Principles From PhRMA, BIO Aim For Reg Changes
Manufacturer communications with providers and payers could include real-world evidence and pharmacoeconomic information, associations urge.
US Price Negotiation Hearing Lays The Groundwork For Future Improvements
The pharma industry is hoping that litigation might end Medicare price negotiation before it begins. But a House hearing also starts the process of developing legislative improvements that might be viable in years to come – starting with trying to restore the lifespan of small molecules.